WallStreetZenWallStreetZen

NASDAQ: PCRX
Pacira Biosciences Inc Stock

$19.37-0.85 (-4.2%)
Updated Jul 19, 2024
PCRX Price
$19.37
Fair Value Price
N/A
Market Cap
$901.60M
52 Week Low
$19.34
52 Week High
$40.16
P/E
12.74x
P/B
1.01x
P/S
1.99x
PEG
0.4x
Dividend Yield
N/A
Revenue
$681.75M
Earnings
$70.47M
Gross Margin
73.1%
Operating Margin
16.99%
Profit Margin
10.3%
Debt to Equity
0.78
Operating Cash Flow
$185M
Beta
0.85
Next Earnings
Jul 31, 2024
Ex-Dividend
N/A
Next Dividend
N/A

PCRX Overview

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

Zen Score

Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PCRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

PCRX ($19.37) is trading below its intrinsic value of $25.27, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PCRX is good value based on its earnings relative to its share price (12.74x), compared to the US market average (29.62x)
P/E vs Market Valuation
PCRX is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more PCRX due diligence checks available for Premium users.

Be the first to know about important PCRX news, forecast changes, insider trades & much more!

PCRX News

Valuation

PCRX fair value

Fair Value of PCRX stock based on Discounted Cash Flow (DCF)
Price
$19.37
Fair Value
$65.35
Undervalued by
70.36%
PCRX ($19.37) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

PCRX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
12.74x
Industry
-3.43x
Market
29.62x
PCRX is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
PCRX is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

PCRX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.01x
Industry
2.25x
PCRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

PCRX price to earnings growth (PEG)

For valuing profitable companies with growth potential
PCRX is good value based... subscribe to Premium to read more.
PEG Value Valuation

PCRX's financial health

Profit margin

Revenue
$167.1M
Net Income
$9.0M
Profit Margin
5.4%
PCRX's Earnings (EBIT) of $115.85M... subscribe to Premium to read more.
Interest Coverage Financials
PCRX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$1.6B
Liabilities
$691.2M
Debt to equity
0.78
PCRX's short-term assets ($543.11M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PCRX's long-term liabilities ($597.72M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PCRX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PCRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$49.1M
Investing
-$15.5M
Financing
-$2.8M
PCRX's operating cash flow ($184.62M)... subscribe to Premium to read more.
Debt Coverage Financials

PCRX vs Pharmaceutical Stocks

TickerMarket Cap1d %P/EP/B
PCRX$901.60M-4.20%12.74x1.01x
CRON$909.19M+1.28%-17.00x0.84x
HROW$884.90M+1.71%-27.18x14.61x
PAHC$754.99M-1.01%56.48x2.80x
EOLS$748.82M+1.96%-11.50x40.60x

Pacira Biosciences Stock FAQ

What is Pacira Biosciences's quote symbol?

(NASDAQ: PCRX) Pacira Biosciences trades on the NASDAQ under the ticker symbol PCRX. Pacira Biosciences stock quotes can also be displayed as NASDAQ: PCRX.

If you're new to stock investing, here's how to buy Pacira Biosciences stock.

What is the 52 week high and low for Pacira Biosciences (NASDAQ: PCRX)?

(NASDAQ: PCRX) Pacira Biosciences's 52-week high was $40.16, and its 52-week low was $19.34. It is currently -51.77% from its 52-week high and 0.16% from its 52-week low.

How much is Pacira Biosciences stock worth today?

(NASDAQ: PCRX) Pacira Biosciences currently has 46,546,148 outstanding shares. With Pacira Biosciences stock trading at $19.37 per share, the total value of Pacira Biosciences stock (market capitalization) is $901.60M.

Pacira Biosciences stock was originally listed at a price of $7.02 in Feb 3, 2011. If you had invested in Pacira Biosciences stock at $7.02, your return over the last 13 years would have been 175.93%, for an annualized return of 8.12% (not including any dividends or dividend reinvestments).

How much is Pacira Biosciences's stock price per share?

(NASDAQ: PCRX) Pacira Biosciences stock price per share is $19.37 today (as of Jul 19, 2024).

What is Pacira Biosciences's Market Cap?

(NASDAQ: PCRX) Pacira Biosciences's market cap is $901.60M, as of Jul 21, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Pacira Biosciences's market cap is calculated by multiplying PCRX's current stock price of $19.37 by PCRX's total outstanding shares of 46,546,148.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.